Open HandWomen, justice and the game

Depo Provera Side Effects: Bone Loss, Meningioma Risk and Lawsuits

Updated

Clay model of a pharmacy counter seen from above: a single small medicine vial with a clay-colored cap, a paper prescription bag and a blank desk calendar.

Short answer

Depo-Provera is a progestin shot given every three months to prevent pregnancy. Its label lists irregular bleeding and weight gain as the most common side effects, carries a boxed warning on Depo Provera bone loss and, since December 2025, also warns about meningioma.1 Most federal meningioma lawsuits are being resolved through a settlement program whose registration deadline is November 30, 2026.2

On this page (11)

What Depo-Provera is and how it is given

Depo-Provera is the brand name for depot medroxyprogesterone acetate, usually shortened to DMPA, made by Pfizer. The best-known Depo Provera side effects are irregular bleeding and weight gain.1 The December 2025 meningioma warning is at the center of MDL No. 3140, the federal litigation over the shot, where the court has recorded November 30, 2026 as the deadline for claimants to register for the settlement program.2

The contraceptive version, Depo-Provera CI, is a 150 mg dose given by deep injection into the muscle of the buttock or upper arm every 3 months (13 weeks).1 A lower-dose version, depo-subQ provera 104, puts 104 mg under the skin of the thigh or abdomen every 12 to 14 weeks.3

The American College of Obstetricians and Gynecologists (ACOG) calls it highly effective and notes that its privacy and its schedule of four injections a year make it appealing to many users, especially adolescents.4 The trade-offs sit in the label.

Common Depo Provera side effects on the label

The most common Depo Provera side effects in the prescribing information involve bleeding and weight. In clinical studies, 57 percent of women had irregular bleeding or spotting at 12 months and 32 percent at 24 months. Many stop having periods: by month 24, 68 percent reported none.1

Weight tends to climb with time. From an average starting weight of 136 pounds, women who completed one year gained an average of 5.4 pounds, those who completed two years 8.1 pounds, and those who completed six years 16.5 pounds. Headache (17 percent), abdominal pain or discomfort (11 percent), nervousness (11 percent), dizziness (6 percent) and decreased libido (6 percent) round out the reactions the label reports in more than 5 percent of users.1

Fertility returns slowly. In a large US study of women who stopped the shot to become pregnant, those who conceived did so a median of 10 months after the last injection, with a range of 4 to 31 months, regardless of how long they had used it. The shot does not protect against HIV or other sexually transmitted infections.1

Bone loss: the 2004 boxed warning and what came after

In November 2004 the FDA placed a boxed warning, the most prominent kind, on the label.5 It says that women who use the shot may lose significant bone mineral density, that the loss grows with longer use and may not be completely reversible, and that the shot is not recommended for more than two years unless other methods are inadequate. The current label carries the same warning.1

The loss is steepest early. In a controlled study of adult women, density in the lower spine fell by an average of 2.86 percent after one year and 5.38 percent after five, while the comparison group showed no significant change. Two years after stopping, the loss had partly recovered, and longer use meant less complete recovery. Among adolescents who used the shot for more than two years, hip density had not fully recovered five years after the last injection.1

ACOG reads the same body of evidence less strictly. Its 2014 committee opinion says longitudinal and cross-sectional studies suggest bone density recovers after the shot is stopped, that no high-quality data show whether it changes fracture risk later in life, and that concern about Depo Provera bone loss should not stop clinicians from prescribing it or continuing it beyond two years. The college asks clinicians to discuss the boxed warning with each patient and weigh it against the risks of unintended pregnancy.4

Meningioma and the 2024 French study

Meningiomas are the most common type of primary brain tumor. They form in the meninges, the membranes around the brain and spinal cord. Most are grade 1, low-grade tumors whose cells grow slowly; grade 1 is more common in women.6 Reports of a Depo Provera brain tumor almost always refer to a meningioma.

In March 2024 The BMJ published a national case-control study led by Noémie Roland of EPI-PHARE, the drug-safety research group run by France’s medicines agency and its national health insurance. The team took the 18,061 women in France who had surgery for an intracranial meningioma between 2009 and 2018, matched each with five women of the same birth year and area who had not, and compared which progestogens the two groups had been dispensed.7

For injectable medroxyprogesterone acetate the odds ratio was 5.55: the odds of having used the shot were about five and a half times higher among the women who needed surgery than among the controls. The excess was driven by use lasting a year or longer. Progesterone, dydrogesterone and levonorgestrel intrauterine devices showed no excess risk.7

What the risk means in absolute terms

The study reports relative odds, not the chance that a given woman on the shot will develop a meningioma. Its raw numbers are small. Nine of the 18,061 women who had surgery had used injectable medroxyprogesterone acetate, against 11 of the 90,305 controls. With so few exposed women, the confidence interval is wide, from 2.27 to 13.56.7 A clinician can place that relative figure against a patient’s age, history and length of use.

The December 2025 label change

Pfizer asked the FDA in February 2024 to add a meningioma warning. The agency declined, saying that the findings of observational studies alone did not support it. Pfizer amended and resubmitted the application in June 2025, and in December 2025 the FDA approved meningioma information for both Depo-Provera CI and depo-subQ provera 104.8

The new text is a warning in section 5.4 of the prescribing information, not a boxed warning. It says meningiomas have been reported after repeated use of medroxyprogesterone acetate, primarily with long-term use, tells clinicians to monitor patients for signs and symptoms, and to stop the drug if a meningioma is diagnosed.1

Depo-Provera warnings at a glance

Selected warnings and reactions in the Depo-Provera CI prescribing information, revised December 2025
IssueWhat the label saysWhere in the label
Bone mineral densityLoss may be significant, grows with duration, may not be completely reversible; use beyond 2 years not recommended unless other methods are inadequateBoxed warning; section 5.1
MeningiomaCases reported, mainly with long-term use; monitor for signs and symptoms; stop if diagnosedSection 5.4 (added December 2025)
Bleeding changesIrregular bleeding or spotting in 57% at 12 months; no periods in 68% by month 24Sections 5.11 and 6.1
Weight gainAverage gain of 5.4 lb after 1 year and 8.1 lb after 2 yearsSection 5.12
Return of fertilityMedian 10 months from last injection to conception (range 4 to 31)Section 5.15

Figures come from the clinical studies summarized in the label.

The Depo-Provera lawsuits: MDL 3140

The lawsuits allege that Pfizer knew of the meningioma risk and failed to warn patients.8 On February 7, 2025, the Judicial Panel on Multidistrict Litigation centralized the federal cases in the Northern District of Florida before Judge M. Casey Rodgers in Pensacola, as MDL No. 3140.9 Each plaintiff there claims to have developed a meningioma after using the shot.

The court’s case management order of July 27, 2026 records where the litigation stood. Member cases had grown to 6,289. The parties had finished discovery on general causation, the question of whether the drug can cause meningioma at all, and had fully briefed their summary judgment and expert-evidence motions, with a hearing set for September 18, 2026.10

By then the litigation had largely turned to settlement. On June 15, 2026, plaintiffs’ leadership counsel announced a settlement of a majority of the claims in the MDL and in New York state court, and the court canceled the first bellwether trial set for December. A Master Settlement Agreement was signed on July 21, 2026. Its terms are confidential; the parties estimated that roughly 80 percent of MDL plaintiffs would be eligible, and eligibility does not depend on any later ruling on the legal issues still open.10

In September 2026 the court opened a fee-free administrative docket for eligible claimants who had signed with a lawyer by June 11, 2026 but had not yet sued, and set November 30, 2026 as the deadline for their complaints, the same date the court had recorded in August as the deadline to register for the settlement program. It kept a December 18 conference on its calendar while registration continued.2,11,12 This section reflects court orders through September 24, 2026.

A contested history

The shot drew controversy long before meningioma. The FDA approved it as a contraceptive only in October 1992, about 25 years after its introduction.13

Outside the United States the arguments were often about consent. In January 2013 the director-general of Israel’s Health Ministry, Roni Gamzu, told doctors not to renew prescriptions for women of Ethiopian origin unless they were confident the patient understood the treatment. The instruction followed a complaint from the Association for Civil Rights in Israel, which cited a health provider’s figures showing that 57 percent of the 5,000 women it injected in 2008 were Ethiopian. Gamzu said the instruction did not mean he accepted the allegations, and Israel denied having any policy to curb the community’s birth rate.14

In Africa the debate was about HIV. A cohort study of 1,314 couples in which only the man had HIV, published online in October 2011, found an adjusted hazard ratio of 1.98 for HIV acquisition among women using hormonal contraception, and its authors advised counseling about a possibly higher risk, especially with injectables.15

The question then went to a randomized trial. ECHO assigned 7,829 women aged 16 to 35 in Eswatini, Kenya, South Africa and Zambia to the shot, a copper IUD or a levonorgestrel implant. HIV incidence was 4.19, 3.94 and 3.31 per 100 woman-years, and no difference was statistically significant.16 On August 29, 2019, the World Health Organization moved progestogen-only injectables from category 2 to category 1, no restriction, for women at high risk of HIV, while still advising condoms where infection is a risk.17

What to ask a clinician

Not every question applies to everyone. Pick the ones that fit.

Questions about Depo-Provera

What are the most common Depo-Provera side effects?

The most common Depo Provera side effects are irregular bleeding or spotting and weight gain. In studies, 57 percent of women had irregular bleeding at 12 months, and women who used the shot for two years gained an average of 8.1 pounds.1

Does Depo-Provera cause brain tumors?

The Depo Provera brain tumor risk that has been studied is meningioma, usually a slow-growing tumor. A 2024 French study found an odds ratio of 5.55 for use of a year or more, and since December 2025 the US label carries a meningioma warning.7,1

Is bone loss from Depo-Provera permanent?

Often only partly reversed. The label reports partial recovery two years after stopping in adults and incomplete hip recovery five years on in adolescents who used it for more than two years; ACOG says the evidence suggests density recovers after the shot is stopped.1,4

Is there a Depo-Provera settlement?

Yes. In MDL No. 3140, which gathers the federal meningioma lawsuits, plaintiffs’ leadership counsel announced a settlement of most claims in June 2026, and a confidential Master Settlement Agreement was signed on July 21, 2026.10 The deadline to register for the settlement program is November 30, 2026, and BrownGreer is the settlement administrator.2 Claimants with questions about eligibility should ask their lawyer or the administrator.

Does Depo-Provera raise the risk of HIV?

The ECHO randomized trial found no statistically significant difference in HIV infection between the shot, a copper IUD and an implant, and WHO lifted its restriction in 2019. The shot does not protect against HIV.16,17

References

Sources 17

  1. Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, prescribing information
    Pfizer (Pharmacia & Upjohn) · DailyMed, U.S. National Library of Medicine
    Government Revised Dec 2025 dailymed.nlm.nih.gov
    ↩
  2. In re: Depo-Provera Products Liability Litigation, Case Management Order No. 14
    U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 738
    Court Aug 10, 2026 flnd.uscourts.gov PDF
    ↩
  3. depo-subQ provera 104 (medroxyprogesterone acetate) injectable suspension, prescribing information
    Pfizer (Pharmacia & Upjohn) · DailyMed, U.S. National Library of Medicine
    ↩
  4. Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects
    American College of Obstetricians and Gynecologists · Obstetrics & Gynecology 2014;123(6):1398–1402
    Research 2014 pubmed.ncbi.nlm.nih.gov
    ↩
  5. FDA “black box” warning on Depo-Provera bone density loss
    American Medical News
    News Dec 13, 2004 amednews.com
    ↩
  6. Meningioma
    National Cancer Institute · NCI-CONNECT, rare brain and spine tumors
    Government cancer.gov
    ↩
  7. Use of progestogens and the risk of intracranial meningioma: national case-control study
    Roland N, Neumann A, Hoisnard L, et al. · BMJ 2024;384:e078078
    Research 2024 bmj.com
    ↩
  8. FDA approves label change for Depo-Provera, adding brain tumor warning
    NBC News
    News Dec 16, 2025 nbcnews.com
    ↩
  9. Transfer Order, In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
    Judicial Panel on Multidistrict Litigation · MDL No. 3140
    Court Feb 7, 2025 jpml.uscourts.gov PDF
    ↩
  10. In re: Depo-Provera Products Liability Litigation, Case Management Order No. 12
    U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 701
    Court Jul 27, 2026 flnd.uscourts.gov PDF
    ↩
  11. In re: Depo-Provera Products Liability Litigation, Case Management Order No. 18 (administrative docket in connection with settlement)
    U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 761
    Court Sep 15, 2026
    ↩
  12. In re: Depo-Provera Products Liability Litigation, Order
    U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 770
    Court Sep 24, 2026
    ↩
  13. Depo-Provera
    Sharts-Hopko NC · MCN, The American Journal of Maternal/Child Nursing 1993;18(2):128
    Research 1993 pubmed.ncbi.nlm.nih.gov
    ↩
  14. Israel to probe birth control for Ethiopian immigrants
    Ynetnews
    News Jan 2013 ynetnews.com
    ↩
  15. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
    Heffron R, Donnell D, Rees H, et al. · Lancet Infectious Diseases 2012;12(1):19–26
    Research 2012 pubmed.ncbi.nlm.nih.gov
    ↩
  16. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial
    ECHO Trial Consortium · Lancet 2019;394(10195):303–313
    Research 2019 pubmed.ncbi.nlm.nih.gov
    ↩
  17. WHO revises recommendations on hormonal contraceptive use for women at high HIV risk
    World Health Organization
    Organization Aug 29, 2019 who.int
    ↩